Clinical Trials Logo

Filter by:
NCT ID: NCT02409342 Completed - Clinical trials for Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Start date: July 20, 2015
Phase: Phase 3
Study type: Interventional

This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either pemetrexed (non-squamous disease) or gemcitabine (squamous disease) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with Stage IV Non-Squamous or Squamous NSCLC.

NCT ID: NCT02409030 Completed - Alzheimer Disease Clinical Trials

Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease

RH-VAL
Start date: January 2014
Phase:
Study type: Observational

The purpose of this study is to validate a diagnostic test that combines different blood markers to identify and correctly classify patients with Alzheimer's disease (AD) compared to individuals with behavioural variant frontotemporal dementia (bvFTD, patient control) versus cognitively healthy individuals (healthy control).

NCT ID: NCT02408939 Completed - Cardiac Arrest Clinical Trials

Steroids and Post-resuscitation Infectious (Septic) Complications

Start date: March 2015
Phase:
Study type: Observational

Postresuscitation disease is characterized by post-insult systemic inflammation, adrenal insufficiency, and circulatory failure. Such severe pathology may be associated with increased susceptibility to infectious complications and increased risk of death due to postresuscitation septic shock. The latter may be attenuated by stress-dose steroids. In this re-analysis of synthesized randomized clinical trial (RCT) data, the investigators will use individual patient data from two prior RCTs of in-hospital cardiac arrest (NCT00411879 & NCT00729794), in order to determine the effect of stress-dose steroids on the severity of postresuscitation infectious complications, and more specifically, on the risk of septic shock-associated death.

NCT ID: NCT02408822 Completed - Clinical trials for Dysfunction of Hemodialysis Vascular Access (Fistula and Graft)

Drug-Eluting Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis (DEBAVAS)

B3AV
Start date: September 29, 2015
Phase: N/A
Study type: Interventional

Paclitaxel is an antiproliferative drug that can limit vascular intimal hyperplasia. Paclitaxel-coated balloons already have indications in the treatment of peripheral arterial disease. This randomized controlled trial is designed to prove the superiority of a drug-eluting balloon catheter (Paclitaxel-coated balloon) over a plain balloon catheter in the treatment of stenosed autogeneous and prosthetic vascular accesses, in hemodialysis patients. The hypothesis is that use of drug-eluting balloon will improve post-interventional patency of the access, and therefore, limit numbers and days of hospitalization for maintenance of hemodialysis vascular accesses.

NCT ID: NCT02408679 Completed - Healthy Volunteers Clinical Trials

Predictive Questionnaire for Vitamin D Insufficiency in Healthy Adults

Start date: January 2015
Phase: N/A
Study type: Observational

The purpose of this clinical study is to evaluate the metrological properties of a questionnaire that aims to identify the vitamin D status in reference to a vitamin D blood dosage.

NCT ID: NCT02408549 Completed - Epilepsy Clinical Trials

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

VALUE
Start date: August 3, 2015
Phase: Phase 3
Study type: Interventional

Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects >= 4 years of age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM SP0982 [NCT02408523] study.

NCT ID: NCT02408523 Completed - Epilepsy Clinical Trials

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

VALOR
Start date: April 2015
Phase: Phase 3
Study type: Interventional

Evaluating efficacy & safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug administration is 28 weeks. Eligible subjects may choose to enter the open-label extension study after completion.

NCT ID: NCT02408393 Completed - Clinical trials for Malignant Neoplasm of Breast

MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery

MIRs03
Start date: March 27, 2015
Phase: Phase 3
Study type: Interventional

Compare the effect of paravertebral block (PVB) with Ropivacaine or placebo on the incidence of chronic pain 3 months after breast cancer surgery.

NCT ID: NCT02408354 Completed - Clinical trials for Alternating Hemiplegia of Childhood

Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood

HEMIHEP
Start date: April 15, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this project is to study the efficacy of triheptanoin oil in patients with Alternating Hemiplegia of Childhood (AHC) due to ATP1A3 gene mutation.

NCT ID: NCT02408250 Completed - Critical Illness Clinical Trials

Tolerance of Early Exercise in Intensive Care Unit

Start date: April 2015
Phase:
Study type: Observational

Practice guidelines recommend early physical therapy in intensive care unit. Feasibility, safety and efficacy are confirmed by growing evidence based data. However, the scientific literature emphasizes the heterogeneity of targeted populations, lack of precisions concerning eligibility criteria, program modalities, timing initiation, progressions and stopping criteria. However, all these results remain to be precised and confirmed. So, the investigators hypothesize that an early exercise program in intensive care unit formalized from a decisional algorithm is well tolerated in clinical practice.